Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inventiva (IVA), Tilray (TLRY) and Apellis Pharmaceuticals (APLS)

Tipranks - Tipranks - Fri Apr 3, 7:14AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inventiva (IVA), Tilray (TLRY) and Apellis Pharmaceuticals (APLS).

End of Quarter Sale - 50% Off TipRanks

Inventiva (IVA)

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Inventiva today and set a price target of $20.00. The company’s shares closed last Wednesday at $5.43.

According to TipRanks.com, Nash is a 5-star analyst with an average return of 23.5% and a 47.6% success rate. Nash covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Rani Therapeutics Holdings, and Madrigal Pharmaceuticals. ;'>

Currently, the analyst consensus on Inventiva is a Strong Buy with an average price target of $15.11, which is a 173.2% upside from current levels. In a report issued on March 19, Truist Financial also initiated coverage with a Buy rating on the stock with a $13.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Tilray (TLRY)

In a report released today, Kenric Tyghe from Canaccord Genuity maintained a Hold rating on Tilray, with a price target of C$9.50. The company’s shares closed last Wednesday at $6.14.

According to TipRanks.com, Tyghe is a 4-star analyst with an average return of 16.2% and a 51.8% success rate. Tyghe covers the Healthcare sector, focusing on stocks such as Planet 13 Holdings, Organigram Global, and Aurora Cannabis. ;'>

Currently, the analyst consensus on Tilray is a Moderate Buy with an average price target of $8.07, which is a 22.1% upside from current levels. In a report issued on March 22, TipRanks – Anthropic also upgraded the stock to Hold with a $6.00 price target.

Apellis Pharmaceuticals (APLS)

Wedbush analyst Laura Chico maintained a Hold rating on Apellis Pharmaceuticals today. The company’s shares closed last Wednesday at $40.39.

According to TipRanks.com, Chico is a 5-star analyst with an average return of 12.3% and a 51.4% success rate. Chico covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ultragenyx Pharmaceutical, and Maze Therapeutics, Inc. ;'>

Apellis Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $37.53, which is a -7.0% downside from current levels. In a report issued on March 31, Needham also downgraded the stock to Hold.

Read More on IVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).